Analysts Offer Insights on Healthcare Companies: Medline, Inc. Class A (MDLN), Mirum Pharmaceuticals (MIRM) and Revolution Medicines (RVMD)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Medline, Inc. Class A (MDLN – Research Report), Mirum Pharmaceuticals (MIRM – Research Report) and Revolution Medicines (RVMD – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Medline, Inc. Class A (MDLN)
William Blair analyst Brandon Vazquez maintained a Buy rating on Medline, Inc. Class A today. The company’s shares closed last Wednesday at $48.18, close to its 52-week high of $50.28.
According to TipRanks.com, Vazquez is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Medline, Inc. Class A with a $48.39 average price target, a 2.1% upside from current levels. In a report issued on February 12, Evercore ISI also maintained a Buy rating on the stock with a $50.00 price target.
See today’s best-performing stocks on TipRanks >>
Mirum Pharmaceuticals (MIRM)
TD Cowen analyst Joseph Thome maintained a Buy rating on Mirum Pharmaceuticals yesterday and set a price target of $117.00. The company’s shares closed last Wednesday at $108.62.
According to TipRanks.com, Thome is a 5-star analyst with an average return of
Currently, the analyst consensus on Mirum Pharmaceuticals is a Strong Buy with an average price target of $115.82, which is a 7.5% upside from current levels. In a report issued on February 17, RBC Capital also initiated coverage with a Buy rating on the stock with a $130.00 price target.
Revolution Medicines (RVMD)
In a report released yesterday, Charles Zhu from LifeSci Capital maintained a Buy rating on Revolution Medicines, with a price target of $144.00. The company’s shares closed last Wednesday at $103.24.
According to TipRanks.com, Zhu is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Revolution Medicines with a $134.36 average price target, representing a 26.9% upside. In a report released yesterday, Evercore ISI also initiated coverage with a Buy rating on the stock with a $140.00 price target.
